VRDN Valuation

Viridian Therapeutics Inc

Add to Watchlist

Advanced Chart

13.740

+0.190(+1.400%)

Overview
Forecast
Valuation

VRDN Relative Valuation

VRDN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VRDN is overvalued; if below, it's undervalued.

Historical Valuation

Viridian Therapeutics Inc (VRDN) is now in the Fair zone, suggesting that its current forward PS ratio of 6700.18 is considered Fairly compared with the five-year average of 2247.00. The fair price of Viridian Therapeutics Inc (VRDN) is between 6.47 to 13.92 according to relative valuation methord.

Relative Value

Fair Zone

6.47-13.92

Current Price：13.74

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

2.27

P/B

Median3y

4.78

Median5y

3.88

-21.68

FCF Yield

Median3y

-15.39

Median5y

-23.67

Competitors Valuation Multiple

The average P/S ratio for VRDN's competitors is 1117.80, providing a benchmark for relative valuation. Viridian Therapeutics Inc Corp (VRDN) exhibits a P/S ratio of 6700.18, which is 499.41% above the industry average. Given its robust revenue growth of 0.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

VRDN.O

Viridian Therapeutics Inc

6700.18

Average P/S: 1117.80

0.00%